

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A composition comprising an isolated MTb81 antigen from *Mycobacterium tuberculosis*, and an isolated Mo2 antigen from *Mycobacterium tuberculosis*, and a pharmaceutically-acceptable excipient.
2. (Original) The composition of claim 1, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.
3. (Original) The composition of claim 2, wherein the fusion polypeptide has the amino acid sequence of TbF14.
4. (Currently amended) A composition comprising an isolated TbRa3 antigen from *Mycobacterium tuberculosis*, an isolated 38kD antigen from *Mycobacterium tuberculosis*, an isolated Tb38-1 antigen from *Mycobacterium tuberculosis*, and an isolated FL TbH4 antigen from *Mycobacterium tuberculosis*, and a pharmaceutically-acceptable excipient.
5. (Original) The composition of claim 4, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.
6. (Original) The composition of claim 5, wherein the fusion polypeptide has the amino acid sequence of TbF15.
7. (Currently amended) A composition comprising an isolated HTCC#1 antigen from *Mycobacterium tuberculosis*, and an isolated TbH9 antigen from *Mycobacterium tuberculosis*, and a pharmaceutically-acceptable excipient.
8. (Original) The composition of claim 7, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.

Appl. No. 09/688,672

Amdt. dated December 23, 2004

Reply to Office Action of September 3, 2004

9-10. (Cancelled)

11. (Currently amended) The composition of claim 10 8, wherein the fusion polypeptide has the amino acid sequence of HTCC#1-TbH9.

12. (Previously presented) The composition of claim 7, comprising a polypeptide comprising amino acids 184-392 of SEQ ID NO:14 from *Mycobacterium tuberculosis*, a TbH9 antigen from *Mycobacterium tuberculosis*, and a polypeptide comprising amino acids 1-129 of SEQ ID NO:14 from *Mycobacterium tuberculosis*.

13. (Original) The composition of claim 12, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.

14. (Previously presented) The composition of claim 13, wherein the fusion polypeptide has the amino acid sequence of SEQ ID NO:14 (184-392)/TbH9/ SEQ ID NO:14 (1-129).

15. (Currently amended) A composition comprising an isolated TbRa12 antigen from *Mycobacterium tuberculosis* and an isolated HTCC#1 antigen from *Mycobacterium tuberculosis*, and a pharmaceutically-acceptable excipient.

16. (Original) The composition of claim 15, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.

17. (Original) The composition of claim 16, wherein the fusion polypeptide has the amino acid sequence of TbRa12-HTCC#1.

18. (Currently amended) A composition comprising at least two heterologous isolated antigens from *Mycobacterium tuberculosis* and a pharmaceutically-acceptable excipient, wherein the antigen is selected from the group consisting of MTb81, Mo2, TbRa3, 38kD, Tb38-1 (MTb11), FL TbH4, HTCC#1 (Mtb40), TbH9, MTCC#2 (Mtb41), DPEP, DPPD, TbRa35,

Appl. No. 09/688,672

Amdt. dated December 23, 2004

Reply to Office Action of September 3, 2004

TbRa12, MTb59, MTb82, Erd14 (Mtb16), FL TbRa35 (Mtb32A), DPV (Mtb8.4), MSL (Mtb9.8), MTI (Mtb9.9A, also known as MTI-A), ESAT-6, α -crystalline, and 85 complex.

19. (Original) The composition of claim 18, wherein the antigens are covalently linked, thereby forming a fusion polypeptide.

20. (Original) The composition of claim 1, 4, 7, 15, or 18, wherein the antigens are covalently linked via a chemical linker.

21. (Original) The composition of claim 20, wherein the chemical linker is an amino acid linker.

22. (Previously presented) The composition of claim 1, 4, 7, 15, or 18, further comprising at least one additional isolated antigen from a *Mycobacterium tuberculosis*, wherein the antigen is selected from the group consisting of MTb81, Mo2, TbRa3, 38kD, Tb38-1 (MTb11), FL TbH4, HTCC#1 (Mtb40), TbH9, MTCC#2 (Mtb41), DPEP, DPPD, TbRa35, TbRa12, MTb59, MTb82, Erd14 (Mtb16), FL TbRa35 (Mtb32A), DPV (Mtb8.4), MSL (Mtb9.8), MTI (Mtb9.9A, also known as MTI-A), ESAT-6, α -crystalline, and 85 complex.

23. (Original) The composition of claim 1, 4, 7, 15, or 18, further comprising an adjuvant.

24. (Original) The composition of claim 23, wherein the adjuvant comprises QS21 and MPL.

25. (Previously presented) The composition of claim 23, wherein the adjuvant is selected from the group consisting of pVac, BCG, lipid A, Freund's complete adjuvant, Freund's incomplete adjuvant, Merck Adjuvant 65, aluminum phosphate, alum, quil A, 3D-MPL, QS7, β -escin, digitonin, ENHANZYN, MPL, QS21, CWS, TDM, AGP, CPG, Leif, saponin, and saponin mimetics.

Appl. No. 09/688,672

Amdt. dated December 23, 2004

Reply to Office Action of September 3, 2004

26. (Original) The composition of claim 1, 4, 7, 15, or 18, further comprising BCG.

27. (Previously presented) The composition of claim 1, 4, 7, 15, or 18, further comprising an isolated NS1 antigen from *Mycobacterium tuberculosis*.

28-104. (Cancelled)

105. (Previously presented) A fusion protein comprising an MTb81 antigen from *Mycobacterium tuberculosis*, and an Mo2 antigen from *Mycobacterium tuberculosis*.

106. (Original) The protein of claim 105, wherein the fusion polypeptide has the amino acid sequence of TbF14.

107. (Previously presented) A fusion protein comprising a TbRa3 antigen from *Mycobacterium tuberculosis*, a 38kD antigen from *Mycobacterium tuberculosis*, a Tb38-1 antigen from *Mycobacterium tuberculosis*, and a FL TbH4 antigen from *Mycobacterium tuberculosis*.

108. (Original) The protein of claim 107, wherein the fusion polypeptide has the amino acid sequence of TbF15.

109. (Previously presented) A fusion protein comprising an HTCC#1 antigen from *Mycobacterium tuberculosis*, and a TbH9 antigen from *Mycobacterium tuberculosis*.

110. (Cancelled)

111. (Previously presented) The protein of claim 109, wherein the fusion polypeptide has the amino acid sequence of HTCC#1-TbH9.

112. (Previously presented) The protein of claim 109, comprising a polypeptide comprising amino acids 184-392 of SEQ ID NO:14 from *Mycobacterium tuberculosis*, a TbH9

PATENT

Appl. No. 09/688,672

Amdt. dated December 23, 2004

Reply to Office Action of September 3, 2004

antigen from *Mycobacterium tuberculosis*, and a polypeptide comprising amino acids 1-129 of SEQ ID NO:14 from *Mycobacterium*.

113. (Previously presented) The protein of claim 112, wherein the fusion polypeptide has the amino acid sequence of SEQ ID NO:14 (184-392)/TbH9/SEQ ID NO:14 (1-129).

114. (Previously presented) A fusion protein comprising a TbRa12 antigen from *Mycobacterium tuberculosis*, and an HTCC#1 antigen from *Mycobacterium tuberculosis*.

115. (Original) The protein of claim 114, wherein the fusion polypeptide has the amino acid sequence of TbRa12-HTCC#1.